Evidence map›Paper›PMID 38837043›Full record

ArticleDialogues in clinical neuroscience2024

The impact of testosterone-lowering medication on recidivism in individuals convicted of sexual offenses.

Julia Sauter, Laura M Lingenti, Martin Rettenberger, Daniel Turner, Peer Briken, Tatjana Voß

Abstract read
In one paragraph

Article in Dialogues in clinical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia SauterDepartment of Psychology, University of Kassel, Kassel, Germany.ORCID 0000-0001-8718-126X
Laura M LingentiInstitute of Health, Institute of Forensic Psychiatry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Martin RettenbergerDepartment of Psychology, Johannes Gutenberg-University (JGU), Mainz, Germany.ORCID 0000-0002-0979-4295
Daniel TurnerDepartment of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany.ORCID 0000-0003-2021-8253
Peer BrikenInstitute for Sex Research, Sexual Medicine, and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tatjana VoßInstitute of Health, Institute of Forensic Psychiatry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of individuals who have committed sexual offences with Testosterone-Lowering Medication (TLM) is a comparatively intrusive kind of intervention, which regularly takes place in coercive contexts. Thus, the question of efficacy, but also the question of who should be treated, when and for how long, are of great importance.

methodsRecidivism rates of TLM-treated high-risk individuals (+TLM;

resultsGroup differences suggested a higher initial risk of + TLM (e.g. higher ris-assessment, previous convictions). Despite the increased risk, after an average time at risk of six years, +TLM recidivated significantly less often and significantly later than - TLM (27.8% vs. 51.9%). Such an effect was also found for violent (1.9% vs. 15.2%), but not for sexual (5.6% vs. 10.1%) and serious recidivism (5.6% vs. 10.1%), which could be explained partly by the small number of cases. In the course of treatment, TLM proved to be a significant variable for a positive process, whereas a high risk-assessment score indicated a rather negative course. In total,

conclusionThe results support the efficacy of TLM, particularly in the group of high-risk offenders.

Indexed as

RecidivismSex OffensesTestosteroneAdultCriminalsFemaleHumansMaleMiddle AgedPsychotherapyTreatment OutcomeYoung AdultTestosteroneAntiandrogensGnRH-agonistspaedophilic disorderparaphilic disorderrecidivism risk

Identifiers

PMID38837043
PMCPMC11155425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.